-
Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology(Jul 3, 2009)
New Brunswick, N.J. (July 3, 2009) -- Johnson & Johnson (NYSE: JNJ) today announced that the initial offering period of its tender offer for all outstanding shares of common stock of Cougar Biotechnology, Inc. (NASDAQ: CGRB) expired at midnight (Eastern time) on July 2, 2009. The offer was conducted through a wholly owned subsidiary of Johnson & Johnson named Kite Merger Sub, Inc.....
-
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer’s Immunotherapy Program and Equity Investment(Jul 2, 2009)
New Brunswick, N.J., and Dublin, Ireland, July 2, 2009 – Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer’s Immunotherapy Program (AIP Program), through a newly formed company. In addition, Johnson & Johnson, through its affiliate, will invest $1 billion in Elan in exchange for newly issued American Depositary Receipts (ADRs) of Elan which will represent 18.4% of Elan’s outstanding ordinary shares.....
-
Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research(Jul 1, 2009)
London, (July 1, 2009) – Johnson & Johnson today announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin® (trastuzumab)1, is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned scientists selected Dr. Ullrich, who on September 8 will receive a $100,000 prize during a ceremony in Beerse, Belgium.....
-
Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories (Jun 29, 2009)
Horsham, PA (June 29, 2009) – Centocor Ortho Biotech Inc. announced today that a federal jury has returned a verdict of $1.67 billion against Abbott Laboratories in a patent infringement suit.
-
SIMPONIâ„¢ (Golimumab) Receives Positive Opinion from Chmp for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis(Jun 26, 2009)
Horsham, PA and Kenilworth, NJ (June 25, 2009) – Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion recommending the approval of SIMPONI™ (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS). .....
-
Girls’ Overall Self-Worth Improves With Contact Lens Wear, Study Shows(Jun 25, 2009)
Jacksonville, FL (June 25, 2009) – Contact lenses improve the overall self-worth of girls, according to data drawn from a three-year multi-site study assessing the effects of glasses and contact lenses on the self-perception of nearsighted children ages eight to 11 years. The research, a unique collaboration between psychology and optometry, further demonstrates the value-added benefits of contact lens wear beyond vision correction.....
-
Ortho Clinical Diagnostics Opens State-Of-The-Art Manufacturing Facility In Pencoed, Wales(Jun 25, 2009)
Pencoed, Wales (24 June 2009) –Ortho Clinical Diagnostics (OCD) today announced the opening of a new, state-of-the-art manufacturing facility in Pencoed, Wales. The occasion was marked by an official visit from HRH The Prince of Wales, who spoke at the opening ceremony.....
-
NUCYNTAâ„¢ (tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain (Jun 23, 2009)
Raritan, NJ – June 23, 2009 – Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA™ (tapentadol) CII immediate release tablets. This new medication for the relief of moderate to severe acute pain in patients 18 years of age or older is now available by prescription only in 50-mg, 75-mg and 100-mg tablets, announced PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.....
-
Biosense Webster To Showcase CARTO® 3 System at EUROPACE(Jun 22, 2009)
Berlin, Germany (June 21, 2009) – Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase the CARTO® 3 System, the most advanced three-dimensional imaging technology for use by electrophysiologists in treating cardiac arrhythmias, commonly referred to as irregular heart rhythms, here at EUROPACE, the official Congress of the European Heart Rhythm Association.....
-
Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition Of Cougar Biotechnology
(Jun 17, 2009)
New Brunswick, N.J. (June 17, 2009) -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to its previously announced planned acquisition of Cougar Biotechnology (Nasdaq: CGRB). .....
|
World Pharma News RSS Channel
Subscribe to World Pharma News by Email
European Commission - Pharmaceuticals
US Food and Drug Administration 
PharmaNews.eu, an advanced web based news engine, addressed to the European pharmaceutical domain, has been launched. The project was developed to directly connect, promote and disseminate the European pharmaceutical news...